Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval

The world’s best-selling medicine is still adding new uses, and its latest FDA approval marks a first in the cancer immunotherapy class.

Merck & Co.’s Keytruda has received the FDA’s green light for use in combination with chemotherapy, followed by the PD-1 inhibitor as a single agent, in patients with primary advanced or recurrent endometrial cancer, the company said Monday.